Pharmacogenetics and Future Therapeutic Scenarios

What Affects the Prediction of Response to Treatment with Etanercept?

Giuseppe Murdaca, Rossella Gulli, Francesca Spanò, Paola Mandich, Francesco Puppo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Enabling Technology, Genomics, Proteomics Clinical Development Phases I-III Regulatory, Quality, Manufacturing There are five tumor necrosis factor alpha (TNF-α) inhibitors available for clinical use that have demonstrated efficacy as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of immune-mediated diseases. These include the anti-TNF-α monoclonal antibodies infliximab, adalimumab, golimumab, and certolizumab pegol, and the fusion protein, etanercept. The use of pharmacogenetic testing has the potential to increase drug efficiency by identifying genetic factors responsible for a lack of response to, or toxicities from, TNF-α inhibitors, and could be used to individualize therapy. Several studies have reported associations between genetic polymorphisms and the response to etanercept, but most are small and insufficiently powered to detect effect, and markers tend to be more prognostic than predictive of therapeutic response. Limitations of pharmacogenetic studies include the use of single nucleotide polymorphisms (SNPs), genes in linkage with other loci, interaction of environmental factors, and cohort heterogeneity, all of which can complicate the relationship between genetic polymorphisms and treatment response. Further studies are needed for pharmacogenetics to become a routine part of daily clinical therapeutic practice.

Original languageEnglish
Pages (from-to)S7-S10
JournalDrug Development Research
Volume75
DOIs
Publication statusPublished - 2014

Fingerprint

Pharmacogenetics
Tumor Necrosis Factor-alpha
Genetic Polymorphisms
Antirheumatic Agents
Immune System Diseases
Genomics
Proteomics
Single Nucleotide Polymorphism
Anti-Inflammatory Agents
Therapeutics
Monoclonal Antibodies
Technology
Pharmaceutical Preparations
Genes
Pharmacogenomic Testing
Etanercept
Proteins

Keywords

  • etanercept
  • lymphotoxin-α
  • TNF-α gene polymorphisms

ASJC Scopus subject areas

  • Drug Discovery
  • Medicine(all)

Cite this

Pharmacogenetics and Future Therapeutic Scenarios : What Affects the Prediction of Response to Treatment with Etanercept? / Murdaca, Giuseppe; Gulli, Rossella; Spanò, Francesca; Mandich, Paola; Puppo, Francesco.

In: Drug Development Research, Vol. 75, 2014, p. S7-S10.

Research output: Contribution to journalArticle

Murdaca, Giuseppe ; Gulli, Rossella ; Spanò, Francesca ; Mandich, Paola ; Puppo, Francesco. / Pharmacogenetics and Future Therapeutic Scenarios : What Affects the Prediction of Response to Treatment with Etanercept?. In: Drug Development Research. 2014 ; Vol. 75. pp. S7-S10.
@article{9dd9f7d8bcec44e49dbcfabaa9d13015,
title = "Pharmacogenetics and Future Therapeutic Scenarios: What Affects the Prediction of Response to Treatment with Etanercept?",
abstract = "Enabling Technology, Genomics, Proteomics Clinical Development Phases I-III Regulatory, Quality, Manufacturing There are five tumor necrosis factor alpha (TNF-α) inhibitors available for clinical use that have demonstrated efficacy as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of immune-mediated diseases. These include the anti-TNF-α monoclonal antibodies infliximab, adalimumab, golimumab, and certolizumab pegol, and the fusion protein, etanercept. The use of pharmacogenetic testing has the potential to increase drug efficiency by identifying genetic factors responsible for a lack of response to, or toxicities from, TNF-α inhibitors, and could be used to individualize therapy. Several studies have reported associations between genetic polymorphisms and the response to etanercept, but most are small and insufficiently powered to detect effect, and markers tend to be more prognostic than predictive of therapeutic response. Limitations of pharmacogenetic studies include the use of single nucleotide polymorphisms (SNPs), genes in linkage with other loci, interaction of environmental factors, and cohort heterogeneity, all of which can complicate the relationship between genetic polymorphisms and treatment response. Further studies are needed for pharmacogenetics to become a routine part of daily clinical therapeutic practice.",
keywords = "etanercept, lymphotoxin-α, TNF-α gene polymorphisms",
author = "Giuseppe Murdaca and Rossella Gulli and Francesca Span{\`o} and Paola Mandich and Francesco Puppo",
year = "2014",
doi = "10.1002/ddr.21185",
language = "English",
volume = "75",
pages = "S7--S10",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Pharmacogenetics and Future Therapeutic Scenarios

T2 - What Affects the Prediction of Response to Treatment with Etanercept?

AU - Murdaca, Giuseppe

AU - Gulli, Rossella

AU - Spanò, Francesca

AU - Mandich, Paola

AU - Puppo, Francesco

PY - 2014

Y1 - 2014

N2 - Enabling Technology, Genomics, Proteomics Clinical Development Phases I-III Regulatory, Quality, Manufacturing There are five tumor necrosis factor alpha (TNF-α) inhibitors available for clinical use that have demonstrated efficacy as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of immune-mediated diseases. These include the anti-TNF-α monoclonal antibodies infliximab, adalimumab, golimumab, and certolizumab pegol, and the fusion protein, etanercept. The use of pharmacogenetic testing has the potential to increase drug efficiency by identifying genetic factors responsible for a lack of response to, or toxicities from, TNF-α inhibitors, and could be used to individualize therapy. Several studies have reported associations between genetic polymorphisms and the response to etanercept, but most are small and insufficiently powered to detect effect, and markers tend to be more prognostic than predictive of therapeutic response. Limitations of pharmacogenetic studies include the use of single nucleotide polymorphisms (SNPs), genes in linkage with other loci, interaction of environmental factors, and cohort heterogeneity, all of which can complicate the relationship between genetic polymorphisms and treatment response. Further studies are needed for pharmacogenetics to become a routine part of daily clinical therapeutic practice.

AB - Enabling Technology, Genomics, Proteomics Clinical Development Phases I-III Regulatory, Quality, Manufacturing There are five tumor necrosis factor alpha (TNF-α) inhibitors available for clinical use that have demonstrated efficacy as monotherapy or in combination with other anti-inflammatory or disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of immune-mediated diseases. These include the anti-TNF-α monoclonal antibodies infliximab, adalimumab, golimumab, and certolizumab pegol, and the fusion protein, etanercept. The use of pharmacogenetic testing has the potential to increase drug efficiency by identifying genetic factors responsible for a lack of response to, or toxicities from, TNF-α inhibitors, and could be used to individualize therapy. Several studies have reported associations between genetic polymorphisms and the response to etanercept, but most are small and insufficiently powered to detect effect, and markers tend to be more prognostic than predictive of therapeutic response. Limitations of pharmacogenetic studies include the use of single nucleotide polymorphisms (SNPs), genes in linkage with other loci, interaction of environmental factors, and cohort heterogeneity, all of which can complicate the relationship between genetic polymorphisms and treatment response. Further studies are needed for pharmacogenetics to become a routine part of daily clinical therapeutic practice.

KW - etanercept

KW - lymphotoxin-α

KW - TNF-α gene polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=84910033378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910033378&partnerID=8YFLogxK

U2 - 10.1002/ddr.21185

DO - 10.1002/ddr.21185

M3 - Article

VL - 75

SP - S7-S10

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

ER -